246 related articles for article (PubMed ID: 23340795)
1. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
Lee J; Gollahon L
Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
3. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
[TBL] [Abstract][Full Text] [Related]
4. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
5. Nek2 as a novel molecular target for the treatment of breast carcinoma.
Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
[TBL] [Abstract][Full Text] [Related]
6. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
Lee J; Gollahon L
Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
8. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.
Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M
Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485
[TBL] [Abstract][Full Text] [Related]
9. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
10. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
[TBL] [Abstract][Full Text] [Related]
11. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
12. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
13. Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.
Redondo M; Téllez T; Roldan MJ; Serrano A; García-Aranda M; Gleave ME; Hortas ML; Morell M
Breast Cancer Res; 2007; 9(6):R86. PubMed ID: 18078515
[TBL] [Abstract][Full Text] [Related]
14. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
Zhang D; Putti TC
Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
18. Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.
Xing Z; Zhang M; Wang X; Liu J; Liu G; Feng K; Wang X
J Mol Histol; 2021 Aug; 52(4):809-821. PubMed ID: 34009515
[TBL] [Abstract][Full Text] [Related]
19. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
20. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.
Kokuryo T; Hibino S; Suzuki K; Watanabe K; Yokoyama Y; Nagino M; Senga T; Hamaguchi M
Cancer Sci; 2016 Sep; 107(9):1315-20. PubMed ID: 27316377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
